Ethyl Pyrrole-2-Carboxylate

Anhydrous aluminum chloride particle morphology governs acylative coupling efficiency of ethyl pyrrole‑2‑carboxylate in tolmetin sodium dihydrate synthesis

The bulk manufacturing of tolmetin sodium dihydrate (USP, EP) relies on ethyl pyrrole‑2‑carboxylate as the sole pyrrole‑bearing starting material. In this route, ethyl pyrrole‑2‑carboxylate undergoes electrophilic substitution at the 5‑position exclusively when the Lewis acid dispersion meets a D₅₀ threshold below 45 µm. Process development records from pilot‑scale campaigns indicate that anhydrous AlCl₃ charged at 2.5–2.7 mol eq relative to ethyl pyrrole‑2‑carboxylate, with 4‑methylbenzoyl chloride held at 1.05–1.10 eq, delivers acylation selectivity above 92% by peak area at 254 nm. The reaction mass is maintained between ‑5 °C and 0 °C in anhydrous dichloromethane (water content <50 ppm by Karl Fischer) under nitrogen blanket in a 5 000 L glass‑lined reactor equipped with a high‑shear rotor‑stator homogenizer. Upon complete consumption of the pyrrole ester, the mixture is quenched into chilled 2 M HCl, the organic layer washed to neutrality, and the solvent swapped to aqueous ethanol. Saponification of the intermediate ester proceeds with 4 eq NaOH at 50 °C, followed by pH adjustment to the isoelectric point of tolmetin free acid (approximately pH 4.8) to precipitate the intermediate. The free acid is then converted to the sodium salt dihydrate in 95% ethanol with 1.02 eq sodium hydroxide, crystallized by controlled cooling at 0.2 °C/min, and vacuum‑dried at 40 °C, 10 mbar for 12 h. Failure to control AlCl₃ moisture uptake—detectable by an exotherm variability exceeding ±3 °C during addition—increases 2‑acyl isomer formation to 8–12% and generates intractable tars when the internal temperature overshoots +3 °C. The final API is specified per USP Tolmetin Sodium Monograph and EP 10.0, with residual solvent limits per ICH Q3C. The manufacturing process is operated under REACH registration and compliance with 21 CFR 211 current good manufacturing practice for finished pharmaceuticals. Terminal dosage forms include 200 mg and 400 mg capsules and film‑coated tablets for the management of rheumatoid arthritis and osteoarthritis.

Synthesis of 2‑(4‑chlorophenyl)pyrrole, the pivotal penultimate intermediate for the pro‑insecticide chlorfenapyr (FAO Specification 418/TC), begins with a Grignard coupling between ethyl pyrrole‑2‑carboxylate and 4‑chlorophenylmagnesium bromide executed under strictly anhydrous conditions. A 2 000 L stainless‑steel reactor, passivated and dried to a dew point below ‑40 °C, is charged with magnesium turnings (1.25 eq) activated with 0.5 mol% iodine in tetrahydrofuran (THF, water <30 ppm). 4‑Chlorobromobenzene (1.20 eq) in THF is added at a rate maintaining the internal temperature below 35 °C. Once Grignard formation is verified by exotherm arrest and negative Gilman test, the solution is cooled to ‑10 °C and ethyl pyrrole‑2‑carboxylate (1.00 eq) in THF is dosed over 4 h. The reaction is aged at ‑5 °C for 12 h, quenched with saturated ammonium chloride, and extracted with methyl tert‑butyl ether. The crude 2‑(4‑chlorophenyl)pyrrole is purified by vacuum distillation (boiling point 112–114 °C at 0.5 mbar) to a chromatographic purity ≥98.5%. Downstream functionalization to chlorfenapyr proceeds via N‑ethoxymethylation with chloromethyl ethyl ether (1.15 eq) in the presence of sodium hydride dispersion (60% in mineral oil, 1.2 eq) at 0–5 °C, followed by bromination with N‑bromosuccinimide (1.05 eq) in dimethylformamide at ‑15 °C, and final trifluoromethylation using methyl fluorosulfonyldifluoroacetate and copper(I) iodide at 80 °C in N‑methyl‑2‑pyrrolidone. Each unit operation is monitored by inline process analytical technology; residual 4‑chlorobiphenyl, a regulated impurity, is controlled at <0.05% w/w. The active ingredient conforms to REACH Annex VII and EPA 40 CFR 180.536 tolerance levels for use on food‑crop commodities. Terminal formulated products are suspension concentrates (240 g a.i./L) applied as foliar miticides and insecticides in cotton, vegetables, and ornamentals.

Why does ethyl pyrrole‑2‑carboxylate deliver a more thermally stable caramel note than alternative pyrrole esters in hard‑boiled candy at processing temperatures exceeding 145 °C?

Ethyl pyrrole‑2‑carboxylate (FEMA 4116, JECFA 1320, EU FL‑no 14.080) withstands the severe thermal load of continuous candy cookers because the ethyl ester moiety exhibits a hydrolytic half‑life of >45 min at pH 5.0 and 150 °C in a 70 °Brix sucrose/glucose syrup matrix, substantially longer than the corresponding methyl or propyl homologues. Formulators targeting a roasted, nut‑like background with subtle coffee‑like facets dissolve the neat ester in 95% food‑grade ethanol or propylene glycol to prepare a 1–10% w/w stock solution prior to incorporation into the flavor base. In the final confectionery item, use levels range from 0.5 mg/kg to 10 mg/kg, with validated sweet spot ranges dependent on matrix composition and thermal history, as summarized in the accompanying table. During production, the flavor premix is injected into the vacuum‑cooked mass at 135–145 °C via a piston metering pump synchronized with a batch‑weighing system, ensuring a residence time below 90 s before depositing into molds. Alternative dosing methods for baked goods employ spray‑dried encapsulates (carrier: gum acacia/maltodextrin at a wall‑to‑core ratio of 4:1) incorporated into dough at 0.05–0.2% to minimize flash‑off during baking. Regulatory compliance extends across GB 2760 (China, flavor number S0392), 21 CFR 172.515, and EU Regulation 1334/2008, with ongoing re‑evaluation by EFSA. Analytical specifications demand ≥98% purity by GC‑FID, with organoleptic limit tests for off‑notes arising from 2‑acetylpyrrole contamination controlled at <0.1%. Finished products span hard‑boiled caramel drops, instant coffee premixes, chocolate‑flavored compound coatings, and UHT‑treated dairy beverages.

Starting from ethyl pyrrole‑2‑carboxylate, the preparation of meso‑substituted BODIPY (4,4‑difluoro‑4‑bora‑3a,4a‑diaza‑s‑indacene) dyes used as fluorescent probes in confocal microscopy and flow cytometry proceeds through a two‑fold acid‑catalyzed condensation with an aromatic aldehyde. In a typical 500 mL jacketed glass reactor shielded from ambient light, ethyl pyrrole‑2‑carboxylate (2.00 eq, 100 mmol) and the selected aldehyde—most commonly benzaldehyde or 4‑formylbenzoic acid for water‑soluble derivatives—(1.00 eq, 50 mmol) are dissolved in anhydrous dichloromethane (250 mL, water <20 ppm). Trifluoroacetic acid (0.10 eq, 5 mmol) is added dropwise under dry nitrogen, and the mixture stirred at 22 ± 2 °C for 16 h until thin‑layer chromatography (silica gel 60 F₂₅₄, hexane/ethyl acetate 8:2 v/v) confirms complete consumption of the aldehyde. The intermediate dipyrromethane is oxidized in situ with 2,3‑dichloro‑5,6‑dicyano‑1,4‑benzoquinone (1.00 eq, 50 mmol) for 30 min at room temperature. Triethylamine (6.00 eq, 300 mmol) is introduced, followed by boron trifluoride diethyl etherate (7.00 eq, 350 mmol) added at 0 °C, and the mixture warmed to 25 °C over 2 h to complete complexation. The crude dye is isolated by aqueous workup, dried over anhydrous sodium sulfate, and purified by flash chromatography (silica gel, 40–63 µm particle size, gradient elution from 15% to 35% ethyl acetate in hexane). Emission properties depend on the aldehyde substituent; with benzaldehyde, the purified BODIPY exhibits λ_abs 504 nm and λ_em 513 nm in ethanol, with a fluorescence quantum yield of 0.72 ± 0.05 measured against fluorescein standard. For bioimaging applications, batches intended for cell‑based assays undergo additional metal‑scavenging treatment (Chelex resin) to reduce transition‑metal content to <1 ppm each of Fe and Cu, aligned with ISO 10993‑5 recommendations when the dye is used in medical device research. The terminal product is supplied as a lyophilized powder or as 1 mg/mL DMSO stock solutions for direct conjugation. Manufacturing is conducted under REACH and RoHS directives, with residual solvents reported per ICH Q3C options where applicable. No dedicated pharmacopoeial monograph exists; however, published data for this specific configuration of BODIPY derived from ethyl pyrrole‑2‑carboxylate are limited to laboratory‑scale and pilot‑scale batches, and users must independently validate batch‑to‑batch photophysical consistency for diagnostic use.